Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a typical antipsychotic of the thioxanthene class. Melitracen is a tricyclic antidepressant (TCA). This combination is used for the treatment of anxiety and depression.
## Primary Indications
* Anxiety
* Depression
## Adult Dosing
* **Initial dose:** 1 tablet (containing 0.5 mg flupentixol and 10 mg melitracen) twice daily, usually in the morning and at noon.
* **Maintenance dose:** May be titrated up to 2 tablets three times daily based on response and tolerability.
* **Maximum dose:** 6 tablets daily.
## Pediatric Dosing
Pediatric use is not established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary. Specific recommendations are not established.
* **Renal Impairment:** Use with caution; dose reduction may be necessary. Specific recommendations are not established.
* **Elderly:** Often more sensitive to the effects of TCAs and antipsychotics. Start with a lower dose and titrate slowly.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or other thioxanthenes/TCAs.
* Depressed patients treated with MAOIs or within 14 days of discontinuing MAOIs.
* Circulatory collapse, CNS depression, coma.
* Blood dyscrasias.
* Untreated narrow-angle glaucoma.
* Malignant hypertension.
## Adverse Effects
Common adverse effects include drowsiness, dry mouth, blurred vision, constipation, urinary retention, dizziness, fatigue, sexual dysfunction, hypotension, tachycardia. Less common but serious effects include extrapyramidal symptoms (EPS), neuroleptic malignant syndrome (NMS), QTc prolongation, cardiac arrhythmias, seizures, suicidal ideation.
## Key Drug Interactions
* **MAOIs:** Risk of serotonin syndrome or hypertensive crisis. Avoid coadministration.
* **Other CNS Depressants (alcohol, benzodiazepines, opioids):** Additive CNS depression.
* **Anticholinergic Drugs:** Increased anticholinergic effects.
* **Potassium-losing Diuretics:** Increased risk of arrhythmias.
* **CYP1A2 Inhibitors:** Increased flupentixol levels.
* **CYP2D6 Inhibitors:** Increased melitracen levels.
## Monitoring
* Signs and symptoms of NMS (fever, muscle rigidity, altered mental status, autonomic instability).
* Signs and symptoms of EPS (akathisia, dystonia, parkinsonism).
* Mental status and mood changes, especially suicidal ideation.
* Cardiac status, particularly in patients with pre-existing heart conditions or those on high doses.
* Blood pressure (orthostatic hypotension).
* Signs of anticholinergic effects.
## Clinical Pearls
* This combination is most effective in patients with both anxiety and depressive symptoms.
* Sedation is a common side effect, often managed by administering doses at bedtime.
* TCAs, including melitracen, have a narrow therapeutic index and can be cardiotoxic in overdose.
* Gradually taper off the medication upon discontinuation to avoid withdrawal symptoms.
***
**Disclaimer:** This information is intended as a quick reference guide only. Always consult the most current prescribing information and relevant clinical guidelines before making therapeutic decisions. Local protocols may dictate specific dosing and management strategies.
